


**INFORMATION DISCLOSURE CITATION**

OMB No. 0651-0011



Atty. Docket No.	2481.1748-00	Serial No.	09/876,091
Applicant	Klaus-Ulrich WEITHMANN		
Filing Date	June 8, 2001	Group:	Unassigned 1627

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
76	Bickett, D. Mark et al., A High Throughput Fluorogenic Substrate for Interstitial Collagenase (MMP-1) and Gelatinase (MMP-9), Analytical Biochemistry, 212:58-64 (1993).
	Fosang, Amanda J. et al., Aggrecan Is Degraded by Matrix Metalloproteinases in Human Arthritis, J. Clin. Invest., 98(10):2292-2299 (1996).
	Knäuper, Vera et al., Biochemical Characterization of Human Collagenase-3, The Journal of Biological Chemistry, 271(3):1544-1550 (January 19, 1996).
	Knight, C. Graham et al., A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases, Federation of European Biochemical Societies Letters, 296(3):263-266 (1992).
	Massova, Irina et al., Matrix metalloproteinases: structures, evolution, and diversification, The FASEB Journal, 12:1075-1095 (1998).
	Nagase, Hideaki et al., Design and Characterization of a Fluorogenic Substrate Selectively Hydrolyzed by Stromelysin 1 (Matrix Metalloproteinase-3), The Journal of Biological Chemistry, 269(33):20952-20957 (1994).
	Niedzwiecki, Lisa et al., Substrate Specificity of the Human Matrix Metalloproteinase Stromelysin and the Development of Continuous Fluorometric Assays, Biochemistry, 31:12618-12623 (1992).
✓	Weithmann, K. U. et al., Effects of tiaprofenic acid on urinary pyridinium crosslinks in adjuvant arthritic rats: Comparison with doxycycline, Inflamm. res., 46:246-252 (1997).

Examiner <i>R. G. Lomen</i>	Date Considered <i>4/12/02</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449 Patent and Trademark Office - U.S. Department of Commerce	